^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IMM-101

i
Other names: IMM-101, IMM 101, heat-killed whole cell Mycobacterium obuense suspension in borate-buffered saline, NCTC 13365, heat killed M. obuense (NCTC) 13365)
Associations
Company:
Immodulon
Drug class:
Dendritic cell activator
Associations
4ms
Trial completion date
|
IMM-101
4ms
New P2 trial • Metastases
|
Keytruda (pembrolizumab) • gemcitabine • IMM-101
1year
Trial primary completion date
|
IMM-101
over1year
COV-IMMUNO: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (clinicaltrials.gov)
P3, N=195, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Oct 2023
Trial completion date • Trial primary completion date
|
IMM-101
2years
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • ICOS (Inducible T Cell Costimulator) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M)
|
IMM-101
over2years
IMM-101-015: A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (clinicaltrials.gov)
P2, N=16, Completed, Immodulon Therapeutics Ltd | Active, not recruiting --> Completed | N=26 --> 16 | Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Jul 2021 --> Dec 2021
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101
almost3years
Enrollment open
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tecentriq (atezolizumab) • oxaliplatin • IMM-101
3years
New P2 trial
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tecentriq (atezolizumab) • oxaliplatin • IMM-101
over3years
A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (clinicaltrials.gov)
P2, N=26, Active, not recruiting, Immodulon Therapeutics Ltd | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Combination therapy • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • IMM-101
almost4years
Clinical • New P2 trial
|
CA 19-9 (Cancer antigen 19-9)
|
IMM-101